Literature DB >> 30188548

Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

Cormac Sheridan.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30188548     DOI: 10.1038/nbt0918-779

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  11 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.

Authors:  Nicole M Kuderer; Kimberly A Burton; Sibel Blau; Andrea L Rose; Stephanie Parker; Gary H Lyman; C Anthony Blau
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

3.  Roche pays $1.9 billion for Flatiron's army of electronic health record curators.

Authors:  Justin Petrone
Journal:  Nat Biotechnol       Date:  2018-04-05       Impact factor: 54.908

4.  Approval of first tumor gene panel sends shockwaves through labs.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2018-02-06       Impact factor: 54.908

5.  Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Gregory A Daniels; David E Piccioni; Santosh Kesari; Teresa L Helsten; Lyudmila A Bazhenova; Julio Romero; Paul T Fanta; Scott M Lippman; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

6.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Authors:  Ferdinandos Skoulidis; Michael E Goldberg; Danielle M Greenawalt; Matthew D Hellmann; Mark M Awad; Justin F Gainor; Alexa B Schrock; Ryan J Hartmaier; Sally E Trabucco; Laurie Gay; Siraj M Ali; Julia A Elvin; Gaurav Singal; Jeffrey S Ross; David Fabrizio; Peter M Szabo; Han Chang; Ariella Sasson; Sujaya Srinivasan; Stefan Kirov; Joseph Szustakowski; Patrik Vitazka; Robin Edwards; Jose A Bufill; Neelesh Sharma; Sai-Hong I Ou; Nir Peled; David R Spigel; Hira Rizvi; Elizabeth Jimenez Aguilar; Brett W Carter; Jeremy Erasmus; Darragh F Halpenny; Andrew J Plodkowski; Niamh M Long; Mizuki Nishino; Warren L Denning; Ana Galan-Cobo; Haifa Hamdi; Taghreed Hirz; Pan Tong; Jing Wang; Jaime Rodriguez-Canales; Pamela A Villalobos; Edwin R Parra; Neda Kalhor; Lynette M Sholl; Jennifer L Sauter; Achim A Jungbluth; Mari Mino-Kenudson; Roxana Azimi; Yasir Y Elamin; Jianjun Zhang; Giulia C Leonardi; Fei Jiang; Kwok-Kin Wong; J Jack Lee; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Vincent A Miller; Garrett M Frampton; Jedd D Wolchok; Alice T Shaw; Pasi A Jänne; Philip J Stephens; Charles M Rudin; William J Geese; Lee A Albacker; John V Heymach
Journal:  Cancer Discov       Date:  2018-05-17       Impact factor: 39.397

7.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

8.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

9.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

10.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Authors:  Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cell       Date:  2018-06-14       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.